Mary Ann Liebert Inc.: Beating COVID-19 Through Genomic Research
June 05, 2020
June 05, 2020
NEW ROCHELLE, New York, June 5 -- Mary Ann Liebert Inc. issued the following news release:
Next-generation sequencing of the COVID-19 virus is providing powerful metagenomic data, which, combined with clinical data, will inform the search for effective treatments, as reported in the peer-reviewed journal Pediatric Allergy, Immunology, and Pulmonology. Click here to read the article now.
"Continued genomic and epigenomic analysis of SARS-CoV-2 is critical," say . . .
Next-generation sequencing of the COVID-19 virus is providing powerful metagenomic data, which, combined with clinical data, will inform the search for effective treatments, as reported in the peer-reviewed journal Pediatric Allergy, Immunology, and Pulmonology. Click here to read the article now.
"Continued genomic and epigenomic analysis of SARS-CoV-2 is critical," say . . .